Diagnosis and clinical severity markers of bullous pemphigoid

Diagnosis and clinical severity markers of bullous pemphigoid

The use of a broad spectrum of novel detection systems for autoantibodies to the basement membrane proteins BP180 and BP230 has greatly facilitated the diagnosis of bullous pemphigoid, which most likely explains its increasing incidence in central Europe. Because the pathogenic relevance of antibodies to human BP180 has been convincingly shown both in vitro and in vivo, repeated testing for the...

Bullous pemphigoid: clinical practice guidelines.

Bullous pemphigoid (BP) is an autoimmune subepidermal bullous disease in which autoantibodies are directed against components of the basement membrane. Most of these antibodies belong to the immunoglobulin G class and bind principally to 2 hemidesmosomal proteins: the 180-kD antigen (BP180) and the 230-kD antigen (BP230). It is the most common blistering disease in the adult population in devel...

Bullous pemphigoid

Bullous pemphigoid

Disease summary: Bullous Pemphigoid is an acquired, chronic, blistering autoimmune subepidermal bullous disease in which autoantibodies are directed against component of basement membrane zone of the skin [1]. It is characterized by formation of cutaneous bullae on the skin and mucous membrane. The pathogenesis involves migration of inflammatory cells into subepithilial tissues due to activatio...

Bullous pemphigoid.

B ullous pemphigoid is an autoimmune disease, which means that the cells in the body that normally fight infection attack the body instead. The body’s immune system is confused and makes an antibody (type of protein used to fight infection) that targets a part of the skin that normally holds it together. The attack on the skin causes blisters (firm, fluid-filled bubbles on the skin) to form. Th...